Catheter Precision, Inc. Announces First International Use of LockeT Device

Catheter Precision, Inc. (NYSE American: VTAK), a leading medical device company in the United States, has reported the inaugural use of its LockeT device outside of the U.S. This significant event took place at the Hamad Medical Corporation Heart Hospital in Doha, Qatar, a principal healthcare provider in the Middle East. The LockeT venous hemostasis device, recognized for its simplicity and efficiency, facilitated early patient mobilization and discharge, marking a pivotal moment in the device's global application.

Following the successful procedures, Dr. Sajad Hayat emphasized the device's simplicity and effectiveness in creating hemostasis, which benefits both patients and medical staff. David Jenkins, CEO of Catheter Precision, Inc., highlighted the immediate recognition of LockeT's value by the medical community. The LockeT is a suture retention device aiding in hemostasis after percutaneous venous punctures and is registered as a Class 1 device with the FDA.

Catheter Precision is committed to improving cardiac arrhythmia treatments through innovative solutions and has continuously worked on advancing its products since its re-incorporation as Ra Medical Systems, Inc. in 2018 and name change to Catheter Precision, Inc. in 2023. The company outlined its forward-looking statements, addressing risks and uncertainties associated with its growth and industry competition.